Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor and Different Radiotherapy Fractionations for HR+/HER2- Breast Cancer: A Phase II Study

NCT06639672 is registered in ClinicalTrials.gov with Lei Liu as lead sponsor.

NCT NCT06639672
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06639672 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor and Different Radiotherapy Fractionations for HR+/HER2- Breast Cancer: A Phase II Study
Lead sponsor
Lei Liu
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 1, 2024
Completion date
May 1, 2031
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hr+her2- breast cancer